Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Chesler

Showing results (11-20 of 115) with videos related to

Pageof 12
Sort By:
Plos One|December 14, 2011
miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAsMarta Terrile, Kenneth Bryan, Lynsey Vaughan, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitorsMark W Richards, Selena G Burgess, Evon Poon, et al.
Plos One|March 19, 2015
Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastomaZai Ahmad, Lukasz Jasnos, Veronica Gil, et al.
Molecular Oncology|December 22, 2015
Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastomaJennifer R Smith, Lucas Moreno, Simon P Heaton, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 2021
Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT)Katrina M Ingley, Debbie Hughes, Michael Hubank, et al.
Journal of Medicinal Chemistry|February 22, 2019
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase SelectivityEllen Watts, David Heidenreich, Elizabeth Tucker, et al.
Frontiers in Oncology|November 10, 2025
Oxphos targeting of <i>MYCN</i>-amplified neuroblastomaSoraya Epp, Donagh Egan, Evon Poon, et al.
Frontiers in Oncology|June 2, 2015
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural CancerTene Aneka Cage, Yvan Chanthery, Louis Chesler, et al.
Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.
Plos One|March 27, 2014
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaYann Jamin, Laura Glass, Albert Hallsworth, et al.
Pageof 12

Showing results (11-20 of 115) with videos related to

Sort By:
Pageof 12
Plos One|December 14, 2011
miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAsMarta Terrile, Kenneth Bryan, Lynsey Vaughan, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitorsMark W Richards, Selena G Burgess, Evon Poon, et al.
Plos One|March 19, 2015
Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastomaZai Ahmad, Lukasz Jasnos, Veronica Gil, et al.
Molecular Oncology|December 22, 2015
Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastomaJennifer R Smith, Lucas Moreno, Simon P Heaton, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 2021
Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT)Katrina M Ingley, Debbie Hughes, Michael Hubank, et al.
Journal of Medicinal Chemistry|February 22, 2019
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase SelectivityEllen Watts, David Heidenreich, Elizabeth Tucker, et al.
Frontiers in Oncology|November 10, 2025
Oxphos targeting of <i>MYCN</i>-amplified neuroblastomaSoraya Epp, Donagh Egan, Evon Poon, et al.
Frontiers in Oncology|June 2, 2015
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural CancerTene Aneka Cage, Yvan Chanthery, Louis Chesler, et al.
Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.
Plos One|March 27, 2014
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaYann Jamin, Laura Glass, Albert Hallsworth, et al.
Pageof 12